Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24

Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplafin. Methods: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which ha...

Full description

Saved in:
Bibliographic Details
Published inActa pharmacologica Sinica Vol. 30; no. 4; pp. 467 - 477
Main Authors Wu, Yu-mei, Zhang, Kang-jian, Yue, Xue-tian, Wang, Yi-qiang, Yang, Yi, Li, Gong-chu, Li, Na, Wang, Yi-gang
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.04.2009
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplafin. Methods: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. Results: The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. Conclusions: This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.
AbstractList The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin. ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.
The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin.AIMThe aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin.ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis.METHODSZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis.The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells.RESULTSThe combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells.This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.CONCLUSIONThis study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.
The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin. ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.
Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin. Methods: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. Results: The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. Conclusion: This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.
Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplafin. Methods: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. Results: The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. Conclusions: This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.
Author Yu-mei WU Kang-jian ZHANG Xue-tian YUE Yi-qiang WANG Yi YANG Gong-chu LI Na LI Yi-gang WANG
AuthorAffiliation Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, China Department of Surgery, Duchang People's Hospital, Jiujiang 332600, China
Author_xml – sequence: 1
  givenname: Yu-mei
  surname: Wu
  fullname: Wu, Yu-mei
  organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University
– sequence: 2
  givenname: Kang-jian
  surname: Zhang
  fullname: Zhang, Kang-jian
  organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University
– sequence: 3
  givenname: Xue-tian
  surname: Yue
  fullname: Yue, Xue-tian
  organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University
– sequence: 4
  givenname: Yi-qiang
  surname: Wang
  fullname: Wang, Yi-qiang
  organization: Department of Surgery, Duchang People's Hospital
– sequence: 5
  givenname: Yi
  surname: Yang
  fullname: Yang, Yi
  organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University
– sequence: 6
  givenname: Gong-chu
  surname: Li
  fullname: Li, Gong-chu
  organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University
– sequence: 7
  givenname: Na
  surname: Li
  fullname: Li, Na
  organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University
– sequence: 8
  givenname: Yi-gang
  surname: Wang
  fullname: Wang, Yi-gang
  email: wangyigang43@163.com
  organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19270721$$D View this record in MEDLINE/PubMed
BookMark eNp1kktv1DAUhS1URB-wYo8sFmwgU78SJ5tKVSlQaRAbWFv2jTNxSeypnRTNv8fRDBQqWNmSv3t0zj0-RUc-eIvQS0pWlPD6XG_TihHSrGj1BJ1QKcpCslIc5XslaSFIzY_RaUq3hHDGafMMHdOGSSIZPUH9te-1BztaP-HQ4WkeQ8RghwG3Vk89NjsMYTTOO7_B4NJ20JPz-IfLb9rj4CEMu8kB1q314d7FOWHQMe4W_vP7y0Ke36wLJp6jp50ekn1xOM_Qtw_XX68-FesvH2-uLtcFCEmmou1MxxqhGZjWAK8oKWVrS81Lki23ANQQzgm0pRFdaWTZQk2s6aw1VdNqxs_QxV53O5vRtpBzRT2obXSjjjsVtFN_v3jXq024V4IQxqomC7w5CMRwN9s0qdGlZSHa2zAnlXdKmKA8g68fgbdhjj6HU4xykrVqkaFXf9r57eNXAxl4uwcghpSi7R4QopZ-Ve5XLf0qWmWaPqLBTbmQsGRxw39m3u1nUlb2GxsffP4bP8SCPvjNXZ5QRsP3zg1WsaaWss6_6CevWcRU
CitedBy_id crossref_primary_10_1007_s00432_014_1835_8
crossref_primary_10_18632_oncotarget_24539
crossref_primary_10_1007_s13277_014_2353_7
crossref_primary_10_4251_wjgo_v16_i7_2867
crossref_primary_10_1007_s13277_015_3098_7
crossref_primary_10_1124_mol_109_061820
crossref_primary_10_3390_ijms23010072
crossref_primary_10_1007_s11010_010_0397_6
crossref_primary_10_1038_cgt_2012_40
crossref_primary_10_1517_14712598_2010_481668
crossref_primary_10_3748_wjg_v22_i1_326
crossref_primary_10_1002_ijc_25948
crossref_primary_10_1089_ars_2017_7058
crossref_primary_10_1089_ars_2017_7157
crossref_primary_10_3109_0284186X_2011_621447
crossref_primary_10_3389_fonc_2023_1172292
crossref_primary_10_1186_s12985_017_0818_1
crossref_primary_10_1016_j_cytogfr_2012_08_004
crossref_primary_10_1016_j_etap_2013_08_004
crossref_primary_10_1016_j_dit_2013_09_001
crossref_primary_10_1007_s10495_016_1276_8
crossref_primary_10_1186_1756_9966_28_81
crossref_primary_10_1186_1750_2187_8_15
crossref_primary_10_3390_inorganics12070177
crossref_primary_10_18632_oncotarget_3769
crossref_primary_10_1007_s13277_013_1149_5
crossref_primary_10_1089_cbr_2014_1642
crossref_primary_10_1021_acs_chemrestox_9b00097
crossref_primary_10_3892_or_2012_1636
crossref_primary_10_3390_cancers12040809
Cites_doi 10.1089/hum.2005.16.845
10.1056/NEJM198706043162302
10.1073/pnas.171315198
10.1038/nrc2167
10.1111/j.1745-7254.2007.00672.x
10.4161/cbt.458
10.1038/sj.cgt.7700954
10.1007/BF00263902
10.1038/sj.gt.3301377
10.1016/0378-4274(89)90125-2
10.1517/14712598.1.3.525
10.1038/sj.cgt.7700915
10.1007/s11010-007-9514-6
10.1007/978-0-387-68969-2_16
10.1016/j.ymthe.2004.03.014
10.1038/sj.cr.7290191
10.1016/S0270-9295(03)00089-5
10.1016/j.ymthe.2004.12.003
10.1038/sj.onc.1204897
10.1038/sj.cr.7310005
10.1038/sj.onc.1205116
10.1038/78638
10.1038/205698a0
ContentType Journal Article
Copyright CPS and SIMM 2009
Copyright Nature Publishing Group Apr 2009
Copyright © 2009 CPS and SIMM 2009 CPS and SIMM
Copyright_xml – notice: CPS and SIMM 2009
– notice: Copyright Nature Publishing Group Apr 2009
– notice: Copyright © 2009 CPS and SIMM 2009 CPS and SIMM
DBID 2RA
92L
CQIGP
W91
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7QR
7T5
7TK
7TO
7U9
7X7
7XB
88E
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7N
M7P
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1038/aps.2009.16
DatabaseName 中文科技期刊数据库
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Immunology Abstracts
Neurosciences Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
ProQuest SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
ProQuest Central Student


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24
EISSN 1745-7254
EndPage 477
ExternalDocumentID PMC4002269
1730258301
19270721
10_1038_aps_2009_16
29877832
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-05
-0E
-Q-
-SE
-S~
.3N
0R~
188
1OC
23M
2RA
2WC
31~
36B
3V.
4.4
53G
5GY
5VR
5VS
6J9
70F
7X7
8-1
88E
8FI
8FJ
8R4
8R5
8RM
92L
92M
9D9
9DE
A8Z
AADWK
AANZL
AAPBV
AAWBL
AAYJO
AAZLF
ABAWZ
ABDEU
ABKZE
ABUWG
ACBMV
ACBRV
ACBYP
ACGFO
ACGFS
ACIGE
ACIWK
ACKTT
ACPRK
ACRQY
ACTTH
ACVWB
ACXQS
ADBBV
ADFRT
ADHDB
ADMDM
ADQMX
ADRAZ
ADYYL
AEDAW
AEFTE
AEJRE
AENEX
AEXYK
AFBPY
AFKRA
AFRAH
AFSHS
AFUIB
AFZJQ
AGAYW
AGEZK
AGGBP
AGHAI
AHMBA
AHSBF
AILAN
AINHJ
AJDOV
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AMRJV
AMYLF
AOIJS
AXYYD
BAWUL
BBAFP
BBNVY
BENPR
BFHJK
BHPHI
BKKNO
BPHCQ
BVXVI
C1A
CAG
CAJEE
CAJUS
CCEZO
CDYEO
CHBEP
CIEJG
CO8
COF
CQIGP
CS3
CW9
CXBCV
DIK
DNIVK
E3Z
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMOBN
F5P
FA0
FDQFY
FERAY
FIZPM
FSGXE
FYUFA
GX1
HCIFZ
HH5
HYE
HZI
HZ~
JSO
JUIAU
JZLTJ
K97
KQ8
LH4
LW6
M1P
M48
M7P
MK0
NQJWS
NYICJ
O9-
OK1
OVD
P2P
P6G
PQEST
PQQKQ
PQUKI
PROAC
PSQYO
Q--
Q-4
Q2X
R-E
RNT
RNTTT
RPM
RT5
S..
SNX
SNYQT
SRMVM
SV3
SWTZT
T8U
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
U1F
U1G
U5E
U5O
UKHRP
UMP
UZ5
W91
~88
~NG
~WA
406
AACDK
AASML
AATNV
AAXDM
ABAKF
ABZZP
ACAOD
ACMJI
ACZOJ
AEFQL
AEMSY
AESKC
AEVLU
AFBBN
AGQEE
AIGIU
AJAOE
ALIPV
CCPQU
DPUIP
FIGPU
HMCUK
IWAJR
LGEZI
LOTEE
NADUK
NXXTH
ROL
SOHCF
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
SOJ
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7T5
7TK
7TO
7U9
7XB
8FD
8FE
8FH
8FK
ABRTQ
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
LK8
M7N
P64
PJZUB
PKEHL
PPXIY
PQGLB
PRINS
PUEGO
7X8
5PM
ID FETCH-LOGICAL-c470t-dfbf294a2cbdbc361057de5a350270dcc1b0330cd5b4f5b75dc80ebfeeb69da23
IEDL.DBID M48
ISSN 1671-4083
1745-7254
IngestDate Thu Aug 21 18:20:22 EDT 2025
Thu Jul 10 18:19:54 EDT 2025
Sat Aug 23 13:25:05 EDT 2025
Thu Apr 03 07:01:37 EDT 2025
Thu Apr 24 22:51:00 EDT 2025
Tue Jul 01 02:04:08 EDT 2025
Fri Feb 21 02:38:44 EST 2025
Thu Nov 24 20:33:35 EST 2022
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords apoptosis
MDA-7/IL-24
oncolytic adenovirus
cisplatin
Language English
License http://www.springer.com/tdm
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c470t-dfbf294a2cbdbc361057de5a350270dcc1b0330cd5b4f5b75dc80ebfeeb69da23
Notes cisplatin; MDA-7/IL-24; oncolytic adenovirus; apoptosis
MDA-7/IL-24
oncolytic adenovirus
R730.53
R735.2
apoptosis
cisplatin
31-1347/R
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.nature.com/articles/aps200916.pdf
PMID 19270721
PQID 213026984
PQPubID 28815
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4002269
proquest_miscellaneous_67102413
proquest_journals_213026984
pubmed_primary_19270721
crossref_primary_10_1038_aps_2009_16
crossref_citationtrail_10_1038_aps_2009_16
springer_journals_10_1038_aps_2009_16
chongqing_backfile_29877832
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-04-01
PublicationDateYYYYMMDD 2009-04-01
PublicationDate_xml – month: 04
  year: 2009
  text: 2009-04-01
  day: 01
PublicationDecade 2000
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
– name: Shanghai
PublicationTitle Acta pharmacologica Sinica
PublicationTitleAbbrev Acta Pharmacol Sin
PublicationTitleAlternate Acta Pharmacologica Sinica
PublicationYear 2009
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Fisher, Gopalkrishnan, Chada, Ramesh, Grimm, Rosenfeld (CR4) 2003; 2
Hajra, Tan, Liu (CR23) 2008; 622
Zhao, Gu, Dong, Zhang, Zhong, He (CR12) 2005; 16
Khuri, Nemunaitis, Ganly, Arseneau, Tannock, Romel (CR20) 2000; 6
Jiang, Lin, Su, Goldstein, Fisher (CR1) 1995; 11
Fillastre, Raguenez-Viotte (CR27) 1989; 46
Kelland (CR13) 2007; 7
Kirn (CR26) 2001; 1
Morton, Rugman, Dorman, Stoney, Wilson, McCormick (CR15) 1985; 15
Miyahara, Banerjee, Kawano, Efferson, Tsuda, Miyahara (CR6) 2006; 13
Zhang, Zou, Luo, Li, Wang, Sun (CR10) 2003; 13
Williams, Birch, Einhorn, Irwin, Greco, Loehrer (CR16) 1987; 316
Nishikawa, Ramesh, Munshi, Chada, Meyn (CR7) 2004; 9
Chada, Cunningham, Zhang, Su, Mhashilkar, Ekmekcioglu (CR9) 2003; 7
Liu, Qiu, Zou, Pei, Gu, Luo (CR11) 2005; 11
Huang, Madireddi, Gopalkrishnan, Leszczyniecka, Su, Lebedeva (CR21) 2001; 20
Chada, Nemunaitis, Tong, Zhang, Su, Mhashilkar (CR8) 2001; 8
Kirn (CR25) 2001; 8
Chada, Mhashilkar, Liu, Nishikawa, Bocangel, Zheng (CR5) 2006; 13
Uyama, Hatano, Maetani, Isoda, Shibata, Taura (CR24) 2008; 35
Pan, Liu, Liu, Cai, Wang, Qian (CR17) 2007; 304
Xiong, Peng, Tan (CR19) 2007; 38
Pan, Zhong, Liu, Liu, Cai, Wang (CR18) 2007; 28
Rosenberg, Vancamp, Krigas (CR14) 1965; 205
Lebedeva, Su, Chang, Kitada, Reed, Fisher (CR2) 2002; 21
Arany, Safirstein (CR28) 2003; 23
Su, Lebedeva, Gopalkrishnan, Goldstein, Stein, Reed (CR3) 2001; 98
Liu, Gu (CR22) 2006; 16
S Chada (BFaps200916_CR9) 2003; 7
PB Fisher (BFaps200916_CR4) 2003; 2
S Chada (BFaps200916_CR5) 2006; 13
N Uyama (BFaps200916_CR24) 2008; 35
D Kirn (BFaps200916_CR25) 2001; 8
EY Huang (BFaps200916_CR21) 2001; 20
QW Pan (BFaps200916_CR17) 2007; 304
XY Liu (BFaps200916_CR22) 2006; 16
H Jiang (BFaps200916_CR1) 1995; 11
J Xiong (BFaps200916_CR19) 2007; 38
XY Liu (BFaps200916_CR11) 2005; 11
Z Su (BFaps200916_CR3) 2001; 98
D Kirn (BFaps200916_CR26) 2001; 1
FR Khuri (BFaps200916_CR20) 2000; 6
KM Hajra (BFaps200916_CR23) 2008; 622
RP Morton (BFaps200916_CR15) 1985; 15
QW Pan (BFaps200916_CR18) 2007; 28
L Kelland (BFaps200916_CR13) 2007; 7
I Arany (BFaps200916_CR28) 2003; 23
L Zhao (BFaps200916_CR12) 2005; 16
S Chada (BFaps200916_CR8) 2001; 8
ZL Zhang (BFaps200916_CR10) 2003; 13
IV Lebedeva (BFaps200916_CR2) 2002; 21
SD Williams (BFaps200916_CR16) 1987; 316
T Nishikawa (BFaps200916_CR7) 2004; 9
R Miyahara (BFaps200916_CR6) 2006; 13
JP Fillastre (BFaps200916_CR27) 1989; 46
B Rosenberg (BFaps200916_CR14) 1965; 205
11313778 - Gene Ther. 2001 Jan;8(2):89-98
17625587 - Nat Rev Cancer. 2007 Aug;7(8):573-84
18031615 - Acta Pharmacol Sin. 2007 Dec;28(12):1996-2004
13680535 - Semin Nephrol. 2003 Sep;23(5):460-4
17593824 - Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):433-6
11526239 - Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10332-7
15194048 - Mol Ther. 2004 Jun;9(6):818-28
2414023 - Cancer Chemother Pharmacol. 1985;15(3):283-9
11850799 - Oncogene. 2002 Jan 24;21(5):708-18
14728805 - Cell Res. 2003 Dec;13(6):481-9
17577631 - Mol Cell Biochem. 2007 Oct;304(1-2):315-23
8545104 - Oncogene. 1995 Dec 21;11(12):2477-86
18546629 - Adv Exp Med Biol. 2008;622:197-208
2437455 - N Engl J Med. 1987 Jun 4;316(23):1435-40
16543916 - Cancer Gene Ther. 2006 Aug;13(8):753-61
16467873 - Cell Res. 2006 Jan;16(1):25-30
10932224 - Nat Med. 2000 Aug;6(8):879-85
16000066 - Hum Gene Ther. 2005 Jul;16(7):845-58
14508078 - Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S23-37
14287410 - Nature. 1965 Feb 13;205:698-9
2650023 - Toxicol Lett. 1989 Mar;46(1-3):163-75
16282987 - Cancer Gene Ther. 2006 May;13(5):490-502
15771956 - Mol Ther. 2005 Apr;11(4):531-41
18487912 - Gan To Kagaku Ryoho. 2008 May;35(5):775-80
11704829 - Oncogene. 2001 Oct 25;20(48):7051-63
11727523 - Expert Opin Biol Ther. 2001 May;1(3):525-38
References_xml – volume: 16
  start-page: 845
  year: 2005
  end-page: 58
  ident: CR12
  article-title: Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer
  publication-title: Hum Gene Ther
  doi: 10.1089/hum.2005.16.845
– volume: 316
  start-page: 1435
  year: 1987
  end-page: 40
  ident: CR16
  article-title: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198706043162302
– volume: 98
  start-page: 10332
  year: 2001
  end-page: 7
  ident: CR3
  article-title: A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.171315198
– volume: 7
  start-page: 573
  year: 2007
  end-page: 84
  ident: CR13
  article-title: The resurgence of platinum-based cancer chemotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2167
– volume: 28
  start-page: 1996
  year: 2007
  end-page: 2004
  ident: CR18
  article-title: Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus
  publication-title: Acta Pharmacol Sin
  doi: 10.1111/j.1745-7254.2007.00672.x
– volume: 2
  start-page: S23
  year: 2003
  end-page: S37
  ident: CR4
  article-title: mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.458
– volume: 13
  start-page: 753
  year: 2006
  end-page: 61
  ident: CR6
  article-title: Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7700954
– volume: 7
  start-page: S446
  year: 2003
  ident: CR9
  article-title: INGN 241 (Ad-mda-7) induces widespread apoptosis and activates the immune system in patients with advanced cancer
  publication-title: Mol Ther
– volume: 15
  start-page: 283
  year: 1985
  end-page: 9
  ident: CR15
  article-title: Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/BF00263902
– volume: 8
  start-page: 89
  year: 2001
  end-page: 98
  ident: CR25
  article-title: Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3301377
– volume: 11
  start-page: 2477
  year: 1995
  end-page: 86
  ident: CR1
  article-title: Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression
  publication-title: Oncogene
– volume: 46
  start-page: 163
  year: 1989
  end-page: 75
  ident: CR27
  article-title: Cisplatin nephrotoxicity
  publication-title: Toxicol Lett
  doi: 10.1016/0378-4274(89)90125-2
– volume: 1
  start-page: 525
  year: 2001
  end-page: 38
  ident: CR26
  article-title: Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712598.1.3.525
– volume: 13
  start-page: 490
  year: 2006
  end-page: 502
  ident: CR5
  article-title: mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7700915
– volume: 35
  start-page: 775
  year: 2008
  end-page: 80
  ident: CR24
  article-title: Efficacy and toxicity of transcatheter arterial chemoembolization with cisplatin suspended in lipiodol for unresectable hepatocellular carcinoma
  publication-title: Gan To Kagaku Ryoho
– volume: 304
  start-page: 315
  year: 2007
  end-page: 23
  ident: CR17
  article-title: Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-007-9514-6
– volume: 622
  start-page: 197
  year: 2008
  end-page: 208
  ident: CR23
  article-title: Defective apoptosis underlies chemoresistance in ovarian cancer
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-0-387-68969-2_16
– volume: 9
  start-page: 818
  year: 2004
  end-page: 28
  ident: CR7
  article-title: Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2004.03.014
– volume: 13
  start-page: 481
  year: 2003
  end-page: 99
  ident: CR10
  article-title: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy
  publication-title: Cell Res
  doi: 10.1038/sj.cr.7290191
– volume: 23
  start-page: 460
  year: 2003
  end-page: 4
  ident: CR28
  article-title: Cisplatin nephrotoxicity
  publication-title: Semin Nephrol
  doi: 10.1016/S0270-9295(03)00089-5
– volume: 11
  start-page: 531
  year: 2005
  end-page: 41
  ident: CR11
  article-title: Effective gene-virotherapy for complete eradication of tumor mediated by the combination of htrail (tnfsf10) and plasminogen k5
  publication-title: Mol Therapy
  doi: 10.1016/j.ymthe.2004.12.003
– volume: 20
  start-page: 7051
  year: 2001
  end-page: 63
  ident: CR21
  article-title: Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204897
– volume: 16
  start-page: 25
  year: 2006
  end-page: 30
  ident: CR22
  article-title: Targeting gene-virotherapy of cancer
  publication-title: Cell Res
  doi: 10.1038/sj.cr.7310005
– volume: 21
  start-page: 708
  year: 2002
  end-page: 18
  ident: CR2
  article-title: The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1205116
– volume: 8
  start-page: S3
  issue: Suppl 2
  year: 2001
  ident: CR8
  article-title: A Phase I dose-escalation study of Ad-mda7 (INGN 241) in patients with advanced carcinoma
  publication-title: Cancer Gene Ther
– volume: 6
  start-page: 879
  year: 2000
  end-page: 85
  ident: CR20
  article-title: A controlled trial of ONYX-015, a replication-selective adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer
  publication-title: Nat Med
  doi: 10.1038/78638
– volume: 38
  start-page: 433
  year: 2007
  end-page: 6
  ident: CR19
  article-title: Effects of adenoviral-mediated mda-7/IL-24 gene infection on the growth and drug-resistance of drug-resistant ovarian cancer cell lines
  publication-title: Sichuan Da Xue Xue Bao Yi Xue Ban
– volume: 205
  start-page: 698
  year: 1965
  end-page: 9
  ident: CR14
  article-title: Inhibition of cell division in by electrolysis products from a platinum electrode
  publication-title: Nature
  doi: 10.1038/205698a0
– volume: 8
  start-page: 89
  year: 2001
  ident: BFaps200916_CR25
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3301377
– volume: 8
  start-page: S3
  issue: Suppl 2
  year: 2001
  ident: BFaps200916_CR8
  publication-title: Cancer Gene Ther
– volume: 16
  start-page: 845
  year: 2005
  ident: BFaps200916_CR12
  publication-title: Hum Gene Ther
  doi: 10.1089/hum.2005.16.845
– volume: 1
  start-page: 525
  year: 2001
  ident: BFaps200916_CR26
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712598.1.3.525
– volume: 20
  start-page: 7051
  year: 2001
  ident: BFaps200916_CR21
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204897
– volume: 16
  start-page: 25
  year: 2006
  ident: BFaps200916_CR22
  publication-title: Cell Res
  doi: 10.1038/sj.cr.7310005
– volume: 15
  start-page: 283
  year: 1985
  ident: BFaps200916_CR15
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/BF00263902
– volume: 7
  start-page: S446
  year: 2003
  ident: BFaps200916_CR9
  publication-title: Mol Ther
– volume: 13
  start-page: 481
  year: 2003
  ident: BFaps200916_CR10
  publication-title: Cell Res
  doi: 10.1038/sj.cr.7290191
– volume: 304
  start-page: 315
  year: 2007
  ident: BFaps200916_CR17
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-007-9514-6
– volume: 7
  start-page: 573
  year: 2007
  ident: BFaps200916_CR13
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2167
– volume: 622
  start-page: 197
  year: 2008
  ident: BFaps200916_CR23
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-0-387-68969-2_16
– volume: 21
  start-page: 708
  year: 2002
  ident: BFaps200916_CR2
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1205116
– volume: 35
  start-page: 775
  year: 2008
  ident: BFaps200916_CR24
  publication-title: Gan To Kagaku Ryoho
– volume: 316
  start-page: 1435
  year: 1987
  ident: BFaps200916_CR16
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198706043162302
– volume: 11
  start-page: 531
  year: 2005
  ident: BFaps200916_CR11
  publication-title: Mol Therapy
  doi: 10.1016/j.ymthe.2004.12.003
– volume: 11
  start-page: 2477
  year: 1995
  ident: BFaps200916_CR1
  publication-title: Oncogene
– volume: 9
  start-page: 818
  year: 2004
  ident: BFaps200916_CR7
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2004.03.014
– volume: 205
  start-page: 698
  year: 1965
  ident: BFaps200916_CR14
  publication-title: Nature
  doi: 10.1038/205698a0
– volume: 38
  start-page: 433
  year: 2007
  ident: BFaps200916_CR19
  publication-title: Sichuan Da Xue Xue Bao Yi Xue Ban
– volume: 46
  start-page: 163
  year: 1989
  ident: BFaps200916_CR27
  publication-title: Toxicol Lett
  doi: 10.1016/0378-4274(89)90125-2
– volume: 13
  start-page: 753
  year: 2006
  ident: BFaps200916_CR6
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7700954
– volume: 2
  start-page: S23
  year: 2003
  ident: BFaps200916_CR4
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.458
– volume: 13
  start-page: 490
  year: 2006
  ident: BFaps200916_CR5
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7700915
– volume: 28
  start-page: 1996
  year: 2007
  ident: BFaps200916_CR18
  publication-title: Acta Pharmacol Sin
  doi: 10.1111/j.1745-7254.2007.00672.x
– volume: 23
  start-page: 460
  year: 2003
  ident: BFaps200916_CR28
  publication-title: Semin Nephrol
  doi: 10.1016/S0270-9295(03)00089-5
– volume: 98
  start-page: 10332
  year: 2001
  ident: BFaps200916_CR3
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.171315198
– volume: 6
  start-page: 879
  year: 2000
  ident: BFaps200916_CR20
  publication-title: Nat Med
  doi: 10.1038/78638
– reference: 16467873 - Cell Res. 2006 Jan;16(1):25-30
– reference: 17625587 - Nat Rev Cancer. 2007 Aug;7(8):573-84
– reference: 11313778 - Gene Ther. 2001 Jan;8(2):89-98
– reference: 8545104 - Oncogene. 1995 Dec 21;11(12):2477-86
– reference: 16000066 - Hum Gene Ther. 2005 Jul;16(7):845-58
– reference: 16543916 - Cancer Gene Ther. 2006 Aug;13(8):753-61
– reference: 13680535 - Semin Nephrol. 2003 Sep;23(5):460-4
– reference: 11850799 - Oncogene. 2002 Jan 24;21(5):708-18
– reference: 18031615 - Acta Pharmacol Sin. 2007 Dec;28(12):1996-2004
– reference: 18487912 - Gan To Kagaku Ryoho. 2008 May;35(5):775-80
– reference: 11704829 - Oncogene. 2001 Oct 25;20(48):7051-63
– reference: 16282987 - Cancer Gene Ther. 2006 May;13(5):490-502
– reference: 14508078 - Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S23-37
– reference: 15771956 - Mol Ther. 2005 Apr;11(4):531-41
– reference: 17577631 - Mol Cell Biochem. 2007 Oct;304(1-2):315-23
– reference: 2437455 - N Engl J Med. 1987 Jun 4;316(23):1435-40
– reference: 14287410 - Nature. 1965 Feb 13;205:698-9
– reference: 15194048 - Mol Ther. 2004 Jun;9(6):818-28
– reference: 2414023 - Cancer Chemother Pharmacol. 1985;15(3):283-9
– reference: 17593824 - Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):433-6
– reference: 14728805 - Cell Res. 2003 Dec;13(6):481-9
– reference: 11526239 - Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10332-7
– reference: 2650023 - Toxicol Lett. 1989 Mar;46(1-3):163-75
– reference: 18546629 - Adv Exp Med Biol. 2008;622:197-208
– reference: 11727523 - Expert Opin Biol Ther. 2001 May;1(3):525-38
– reference: 10932224 - Nat Med. 2000 Aug;6(8):879-85
SSID ssj0032319
Score 2.0301719
Snippet Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells...
Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells...
The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 467
SubjectTerms Adenoviridae - genetics
Antineoplastic Agents - pharmacology
Apoptosis
Biomedical and Life Sciences
Biomedicine
Cell death
Cell Line
Cisplatin - pharmacology
Combined Modality Therapy
Dose-Response Relationship, Drug
Genetic Therapy
Humans
Immunology
Interleukins - genetics
Internal Medicine
MDA-7/IL-24
Medical Microbiology
Neoplasms - pathology
Neoplasms - therapy
Oncolytic Virotherapy
Original
original-article
Pharmacology/Toxicology
Vaccine
流式细胞仪分析
溶瘤腺病毒
白细胞介素24
肿瘤细胞死亡
腺病毒携带
诱导凋亡作用
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXLig8g7Lw4fSA2q0Sewk9glV0Koginpopb1FfqW7Apxtsltp_z0zea2WVhwjW47lGXu-mbG_IeRAJdrluUhDZxMbgr_BQykMfvISvIfUxRrjkOc_s7Mr_n2Wzvq7OU1_rXI4E9uD2lYGY-TTBDNsmRT88_ImxKJRmFztK2g8JI-QuQyVOp-N_hYD6ILoN85ydJME65_nRUxM1bLpuCrjllRhXvnrGzAVu8bpDuK8e3Hyn-xpa5RO98mTHk3S4078T8kD55-Rw4uOjnpzRC-3r6uaI3pIL7ZE1ZvnZH7i5yh0DBDSqqSr9Z-qphjKpxaRIdUbCouj2xoS1CyaJV6c8xRjt1R5WnkYaQNjUwWnV3W7qNcNNaqu8ekUPf96HObTbz_ChL8gV6cnl1_Owr7yQmh4Hq1CW-oykVwlRlttWIbFgK1LFUvBi42sMbGOGIuMTTUvU52n1ojI6dI5nUmrEvaS7PnKu9eEQgfJ0lJqBeCHl0oBxMlM7ISRQpW5C8hkXH6w3OYX8lEViRSgQSwJyKdBIIXpScuxdsbvok2eM1GAJLGUpiziLCAHY-dlx9Vxf7fJINmi37DQNqhXQD6MrbDTcM2Vd9W6KTIEY2DzA_Kq04LtTySsCrjSAcl39GPsgBzeuy1-MW-5vDmCqEwG5OOgSds53TP3N_-d-4Q8HpJdUfyW7K3qtXsHmGml37c74y_0rhje
  priority: 102
  providerName: ProQuest
Title Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24
URI http://lib.cqvip.com/qk/95561A/20094/29877832.html
https://link.springer.com/article/10.1038/aps.2009.16
https://www.ncbi.nlm.nih.gov/pubmed/19270721
https://www.proquest.com/docview/213026984
https://www.proquest.com/docview/67102413
https://pubmed.ncbi.nlm.nih.gov/PMC4002269
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwEB7t48IF8SYUig_LHtCGzcN5-IBQC60WRKsKbaXeIttxaMWSdJMW0X_PTNO06m4PnKIoE8eyx5lvZuxvAM6kp0wUxYFtUi-10d_gtog13fIMvYfAuIrikINheDXm3ybB5AiaYpybAawOunZUT2pc3nz4e7v6hAv-Y31kPL6U86omnnTDYzhFkxRRKYMB36YTfAQxhIPdMCKHKfY3B_XuvEz0CtMi_3mLRmPfTN3Dnve3UN7Jo67NU_8RPNzgStapFeExHJn8CZyPamLq1QW73p2zqi7YORvtKKtXT2Hay6c0_RQqZEXGFsvfRckoqM9SwohMrRiqplpXk2B6Vs1pC13OKIrLZM6KHFtaYdtM4n-s-DMrlxXTsizpEBUbfOnY0eXX77bHn8G437v-fGVvajDYmkfOwk4zlXmCS0-rVGk_pLLAqQmkH6A_66Rau8rxfUengeJZoKIg1bFjVGaMCkUqPf85nORFbl4CQwHhB5lQEmEQz6REsBNq18RaxDKLjAWt7fCjDde_iJkq8USMuuR7FrxvJiTRG_pyqqJxk6zT6H6c4ExSUU2RuKEFZ1vhec3acVis1cxs0mhe4lEqNxQxt-Dt9imuORpzmZtiWSUhwTK0_ha8qLVg9xGBo4JOtQXRnn5sBYjNe_9JPpuuWb05walQWPCu0aRdnw70_dV_yrXgQZMAc9zXcLIol-YN4qiFasNxNInacNrpd7tDvHZ7w9GP9nrl_ANKzSJ3
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5V5QAXVN4mQPfQ9oBqxW97DwhVtFVCk6qHVMrN7MskgtppnIDyo_iPzPiRKLTi1mO0K2e1Mzv7fTu73wAcCE-aOE5C22hP28g3Apsnin4GGbKH0LiSziGHl1HvOvg6Dsc78Kd9C0PXKtuYWAVqXSg6I-96lGGLeBJ8nt3aVDSKkqttBY3aKy7M6jcytvJT_xTNe-h552ejLz27KSpgqyB2FrbOZObxQHhKaqn8iOrcahMKP0SC5milXOkgx1c6lEEWyjjUKnGMzIyREdeCdA4w4j_CfdchrheP1_zOR6hEaNuNYqJlid88B3T8pCtmZa2N6VYiDpMi_36LW9P2ZngH4d69qPlPtrbaBM_34GmDXtlJ7W7PYMfkz-Hoqpa_Xh2z0eY1V3nMjtjVRhh79QImZ_mEnIwOJFmRscXyppgzSh0wTUiUyRVDY8iqZgVT03JGF_VyRmfFTOSsyPFLK_w2Exgti1_T-bJkSszn9FSLDU9P7LjbH9he8BKuH8Qor2A3L3LzBhh24H6YcSkQbAWZEAipIuWaRPFEZLGxoLOefkQK6gfpX6UeT9Bjfc-Cj61BUtWIpFOtjp9plaz3kxQtSaU7eepGFhysO89qbZD7u3Vay6ZNgMC21p0t2F-34sqmORe5KZZlGhH4Q4xhwevaCzZ_wnFWkLpbEG_5x7oDaYZvt-TTSaUdHhBoi7gFh60nbcZ0z9jf_nfs-_C4NxoO0kH_8qIDT9pEm-O-g93FfGneI15byA_VKmHw7aGX5V-P3lg5
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VqYS4IN6YAN1D2wOqFb8fB4QKSdTQNopQK_Vm9uUmAuzUTkD5afw7ZvxIFFpx69Ha1Xq1Mzv7zc7sNwD73BE6DCPf1MpRJvobnhlHkj69FL0HX9uC7iHPx8HJpfflyr_agT_tWxhKq2xtYmWoVS7pjrznUIQtiCOvlzZZEZP-8OP8xqQCUhRobatp1Bpyqle_0XsrP4z6KOoDxxkOLj6fmE2BAVN6obUwVSpSJ_a4I4US0g2o5q3SPnd9dNYsJaUtLPT3pfKFl_oi9JWMLC1SrUUQK06cB2j9d0Nyijqw-2kwnnxtjwEXgRNhbzsIyUmL3OZxoOVGPT4va6ZMu6J0mObZ9Q0eVNtH4y28eztt85_YbXUkDh_DowbLsuNa-Z7Ajs6ewuGkJsNeHbGLzduu8ogdssmGJnv1DKaDbEoqR9eTLE_ZYvkzLxgFEpgiXMrEiqFoRFXBgslZOae0vYzRzTHjGcszHGmFYzOOtjP_NSuWJZO8KOjhFjvvH5thb3RmOt5zuLwXsbyATpZn-hUw7BC7fhoLjtDLSzlHgBVIW0cyjngaagO66-VH3CC_ExtW4sQR6q_rGPC-FUgiG8p0qtzxI6lC926UoCSpkGec2IEB--vO85op5O5u3VaySWMusK1VbgP21q24z2nNeabzZZkEBAURcRjwstaCzU9iXBV05A0It_Rj3YEYxLdbstm0YhL3CMIFsQEHrSZt5nTH3F__d-578AC3ZHI2Gp924WEbdbPsN9BZFEv9FsHbQrxrtgmDb_e9M_8CI89d1A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhancement+of+tumor+cell+death+by+combining+cisplatin+with+an+oncolytic+adenovirus+carrying+MDA-7%2FIL-24&rft.jtitle=Acta+pharmacologica+Sinica&rft.au=Wu%2C+Yu-mei&rft.au=Zhang%2C+Kang-jian&rft.au=Yue%2C+Xue-tian&rft.au=Wang%2C+Yi-qiang&rft.date=2009-04-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=1671-4083&rft.eissn=1745-7254&rft.volume=30&rft.issue=4&rft.spage=467&rft.epage=477&rft_id=info:doi/10.1038%2Faps.2009.16&rft.externalDocID=10_1038_aps_2009_16
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F95561A%2F95561A.jpg